Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 2, 2009, Pages 229-236

  Kikuchi, Masahiro ^a   Tomita, Kengo ^a   Nakahara, Tadaki ^a   Kitamura, Naoto ^a   Teratani, Toshiaki ^a   Irie, Rie ^a   Yokoyama, Hirokazu ^a   Suzuki, Takahiro ^a   Yokoyama, Terufumi ^a   Taguchi, Takashi ^a   Tanaka, Shinobu ^a   Noguchi, Masaaki ^a   Ohkura, Tamiko ^a   Hibi, Toshifumi ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

99mTc phytate scintigraphy; Kupffer cell; Non alcoholic steatohepatitis

Indexed keywords

CHOLINE; METHIONINE; PHYTATE TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; DRUG UPTAKE; EVALUATION; EXPERIMENTAL RAT; FEMALE; HEART FUNCTION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; SCINTIGRAPHY; SPLEEN FUNCTION; ANIMAL; FATTY LIVER; HOSPITALIZATION; LIVER; REPRODUCIBILITY; SCINTISCANNING; WISTAR RAT;

ADULT; ANIMALS; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TECHNETIUM;

EID: 61649099647     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802433249     Document Type: Article

References (18)

1. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-23.
2. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liv Dis 2001;21: 17-26.
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
4. Ishii H. Common pathogenic mechanisms in ASH and NASH. Hepatol Res 2004;28:18-20.
5. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004;40:386-93.
6. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T,Mizutani A, et al. Tumour necrosis factor α signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006;55:415-24.
7. Shiomi S, Kuroki T, Ueda T, Takeda T, Nishiguchi S, Nakajima S, et al. Diagnosis by routine scintigraphy of hepatic reticuloendothelial failure before severe liver dysfunction. Am J Gastroenterol 1996;91:140-2.
8. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
9. Youden WJ. An index for rating diagnostic tests. Cancer 1950;3:32-5.
10. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-5.
11. Tanaka S, Kumashiro R, Tanikawa K. Role of the spleen in endotoxin-induced hepatic injury in chronic alcohol-fed rats. Liver 1992;12:306-12.
12. Riordan SM, Duncombe VM, Thomas MC, Nagree A, Bolin TD, Mclver CJ, et al. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. Gut 2002;50:136-8.
13. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001;48:206-11.
14. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-50.
15. 99mTc-phytate colloid using SPECT: detection of liver cirrhosis. J Nucl Med 2002;43:312-7.
16. Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003;38:32-8.
17. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11:255-9.
18. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.